Epidemiology of HIV/AIDS in women and children in the USA

Acta Paediatrica, International Journal of Paediatrics, Supplement

Volumn 86, Issue 421, 1997, Pages 15-16

  Rogers, M F ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ZIDOVUDINE;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ETHNIC GROUP; HEALTH CARE PERSONNEL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICAL EDUCATION; MORTALITY; NEGRO; OPPORTUNISTIC INFECTION; PERINATAL INFECTION; PNEUMOCYSTIS PNEUMONIA; PRENATAL CARE; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; UNITED STATES; URBAN POPULATION;

EID: 0030849612     PISSN: 08035326     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (12)

1. Centers for Disease Control. National HIV seroprevalence summary: results through 1992. Atlanta, GA: US Department of Health and Human Services, Public Health Service, CDC, 1994
2. Davis SF, Byers RH, Lindegren ML, Caldwell MB, Karon JM, Gwinn M. Prevalence and incidence of vertically acquired HIV infection in the United States. JAMA 1995; 274: 952-5
3. Simonds RJ, Oxtoby MJ, Caldwell MB, Gwinn ML, Rogers MR Pneumocystis carinii pneumonia among US children with perinatally acquired HIV infection. JAMA 1993; 270: 470-3
4. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with human immunodeficiency virus. Morbid Mortal Weekly Rep 1991; 40(RR-2): 1-13
5. Simonds RJ, Lindegren ML, Thomas P, Hanson D, Caldwell B, Scott G, et al. Prophylaxis against Pneumocystis carinii pneumonia among children with perinatally acquired human immunodeficiency virus infection in the United States. N Engl J Med 1995; 332: 786-90
6. Centers for Disease Control. 1995 Revised guidelines for prophylaxis against Pneumocystis carinii pneumonia for children infected with or perinatally exposed to human immunodeficiency virus. Morbid Mortal Weekly Rep 1995; 44(RR-4): 1-11
7. Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. N Engl J Med 1994; 331: 1173-80
8. Centers for Disease Control. Recommendations of the US Public Health Service Task Force on the use of zidovudine to reduce perinatal transmission of human immunodeficiency virus. Morbid Mortal Weekly Rep 1994; 43(RR-11)
9. Centers for Disease Control. US Public Health Service recommendations for human immunodeficiency virus counseling and voluntary testing for pregnant women. Morbid Mortal Weekly Rep 1995; 44(RR-7): 1-15
10. Fiscus SA, Adimora AA, Schoenbach VJ, et al. Perinatal HIV infection and the effect of zidovudine therapy on transmission in rural and urban counties. JAMA 1996; 275: 1483-8
11. Wiznia AA, Crane M, Lambert G, Sansary J, Harris A, Solomon L. Zidovudine use to reduce perinatal HIV type 1 transmission in an urban medical center. JAMA 1996; 275: 1504-6
12. Simonds RJ, Rogers MF. Preventing perinatal HIV infection. How far have we come? JAMA 1996; 275: 1514-5